Literature DB >> 17363731

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Alexandre Theocharides1, Marjorie Boissinot, François Girodon, Richard Garand, Soon-Siong Teo, Eric Lippert, Pascaline Talmant, Andre Tichelli, Sylvie Hermouet, Radek C Skoda.   

Abstract

To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F-positive AML, whereas 9 of 17 patients transformed to JAK2-V617F-negative AML. Microsatellite analysis in a female patient showed that mitotic recombination was not responsible for the transition from JAK2-V617F-positive MPD to JAK2-V617F-negative AML, and clonality determined by the MPP1 polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental X chromosome. In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F-negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. We conclude that JAK2-V617F-positive MPD frequently yields JAK2-V617F-negative AML, and transformation of a common JAK2-V617F-negative ancestor represents a possible mechanism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363731     DOI: 10.1182/blood-2006-12-062125

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  96 in total

Review 1.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.

Authors:  Andreas Kreft; Thomas Kindler; Erik Springer; Charles James Kirkpatrick
Journal:  Virchows Arch       Date:  2011-10-18       Impact factor: 4.064

Review 3.  Do we know more about essential thrombocythemia because of JAK2V617F?

Authors:  Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

4.  Competing cell clones in myeloproliferative neoplasm.

Authors:  Aref Al-Kali; Srdan Verstovsek; Hagop Kantarjian; Rajyalakshmi Luthra; Jorge Cortes
Journal:  Blood       Date:  2010-12-02       Impact factor: 22.113

Review 5.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

6.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

7.  JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Authors:  Sven Schwemmers; Britta Will; Cornelius F Waller; Khadija Abdulkarim; Peter Johansson; Björn Andreasson; Heike L Pahl
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

8.  Myeloid sarcoma in essential thrombocythemia that transformed into acute myeloid leukemia.

Authors:  Hisaharu Shikata; Takuya Matumoto; Hiroki Teraoka; Masahiko Kaneko; Mamoru Nakanishi; Tadashi Yoshino
Journal:  Int J Hematol       Date:  2009-01-27       Impact factor: 2.490

Review 9.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 10.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.